About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
2don MSN
Small differences in cell structures called microtubules determine how well cancer drug performs
A research team from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), ...
Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...
Olvi-Vec shows potential in treating advanced lung cancer, demonstrating tumor shrinkage and disease control in patients unresponsive to platinum-based treatments. The investigational therapy is an ...
A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 patients with small cell lung cancer and brain metastases, finding they ...
Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer. During the CURE Educated Patient® Lung Cancer Summit, held in tandem with the 2025 PER® New York ...
Please provide your email address to receive an email when new articles are posted on . Patients with small cell lung cancer who had higher levels of detectable ctDNA mutations at diagnosis had worse ...
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
What Is Hernexeos, and Why Does It Matter? Hernexeos (zongertinib) is a prescription medicine known as a kinase inhibitor that is used for treating adults with advanced non-small-cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results